title: Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.
abstract: To assess the long-term cardioprotective effect of bisoprolol in a randomized high-risk population after successful major vascular surgery. High-risk patients were defined by the presence of one or more cardiac risk factor(s) and a dobutamine echocardiography test positive for ischaemia.
  
  
  
  1351 patients were screened prior to surgery, 846 patients had one or more risk factor(s), and 173 of these patients also had ischaemia during dobutamine echocardiography. One hundred and twelve patients could be randomized for additional bisoprolol therapy or standard care. Eleven patients died in the peri-operative period (up to 1 month after surgery). Randomized patients continued bisoprolol or standard care after surgery. During follow-up of 101 survivors (median 22 months, range 11-30) cardiac death or myocardial infarction was noted. No patient was lost during follow-up. Results The incidence of cardiac events during follow-up in the bisoprolol group was 12% vs 32% in the standard care group (P=0.025). Cardiac death occurred in 15 patients, nine patients in the standard care and in six in the bisoprolol group; myocardial infarction occurred in six patients, five in the standard care and one in the bisoprolol group. The odds ratio for cardiac death or myocardial infarction after surgery in high-risk patients with additional bisoprolol therapy was 0.30 (0.11-0.83).
  
  
  
  Bisoprolol significantly reduced long-term cardiac death and myocardial infarction in high-risk patients after successful major cardiac vascular surgery.
authors.affiliation: Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: Poldermans
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: I R
authors.initials: IR
authors.lastname: Thomson
authors.forename: B
authors.initials: B
authors.lastname: Paelinck
authors.forename: L L
authors.initials: LL
authors.lastname: van de Ven
authors.forename: M G
authors.initials: MG
authors.lastname: Scheffer
authors.forename: G
authors.initials: G
authors.lastname: Trocino
authors.forename: C
authors.initials: C
authors.lastname: Vigna
authors.forename: H F
authors.initials: HF
authors.lastname: Baars
authors.forename: H
authors.initials: H
authors.lastname: van Urk
authors.forename: J R
authors.initials: JR
authors.lastname: Roelandt
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001012:Aorta, Abdominal / Q000601:surgery; D017298:Bisoprolol / Q000627:therapeutic use*; D004280:Dobutamine; D004452:Echocardiography; D005263:Femoral Artery / Q000601:surgery; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000401:mortality* / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging; D011183:Postoperative Complications / Q000517:prevention & control*; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014656:Vascular Surgical Procedures
chemical_list: D000319:Adrenergic beta-Antagonists; D004280:Dobutamine; D017298:Bisoprolol